DrugPatentWatch Database Preview
Drugs in Development Information for Ergonovine
» See Plans and Pricing
What is the drug development status for Ergonovine?
Ergonovine is an investigational drug.
There have been 10 clinical trials for Ergonovine.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2018.
The most common disease conditions in clinical trials are Hemorrhage, Postpartum Hemorrhage, and Uterine Inertia. The leading clinical trial sponsors are Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Turin, Italy, and Johns Hopkins University.
There are four hundred and eighty-three US patents protecting this investigational drug and three international patents.
Summary for Ergonovine
| US Patents | 483 |
| International Patents | 3,691 |
| US Patent Applications | 724 |
| WIPO Patent Applications | 916 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2018-12-01) |
| Vendors | 16 |
Recent Clinical Trials for Ergonovine
| Title | Sponsor | Phase |
|---|---|---|
| Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients | Nicole M. Masse | Phase 4 |
| Effect of Amlodipine Versus Amlodipine Combined With Atorvastatin on the Coronary Vasospastic Angina | Kosin University Gospel Hospital | Phase 4 |
| Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial | Brigham and Women's Hospital | Phase 4 |
Clinical Trial Summary for Ergonovine
Top disease conditions for Ergonovine
Top clinical trial sponsors for Ergonovine
US Patents for Ergonovine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ergonovine | Start Trial | Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof | Gel-Del Technologies, Inc. (St. Paul, MN) | Start Trial |
| Ergonovine | Start Trial | Methods and systems for the delivery of a therapeutic agent | UNIVERSITY OF ICELAND (Reykjavik, IS) | Start Trial |
| Ergonovine | Start Trial | Pyrimidines as sodium channel blockers | Purdue Pharma L.P. (Stamford, CT) | Start Trial |
| Ergonovine | Start Trial | Treatment of sexual dysfunction | Rejoy (Irvine, CA) | Start Trial |
| Ergonovine | Start Trial | Compositions and methods for prophylaxis and treatment of addictions | Omeros Corporation (Seattle, WA) | Start Trial |
| Ergonovine | Start Trial | Crystallization method and bioavailability | GRUNENTHAL GMBH (DE) | Start Trial |
| Ergonovine | Start Trial | Substituted piperidin-4-amino-type compounds and uses thereof | Purdue Pharma L.P. (Stamford, CT) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ergonovine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ergonovine | World Intellectual Property Organization (WIPO) | WO2010057177 | 2028-11-17 | Start Trial |
| Ergonovine | Argentina | AR088029 | 2031-09-02 | Start Trial |
| Ergonovine | Australia | AU2012300567 | 2031-09-02 | Start Trial |
| Ergonovine | Canada | CA2846463 | 2031-09-02 | Start Trial |
| Ergonovine | Cyprus | CY1119327 | 2031-09-02 | Start Trial |
| Ergonovine | Denmark | DK2753606 | 2031-09-02 | Start Trial |
| Ergonovine | European Patent Office | EP2753606 | 2031-09-02 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
